Mitochondrial Support
Mitochondrial dysfunction is increasingly recognized as central to ME/CFS pathophysiology. Multiple supplements targeting mitochondrial function are widely used, though evidence quality varies. These interventions aim to support ATP production, reduce oxidative stress, and improve electron transport chain efficiency.
1 Coenzyme Q10 (CoQ10)
Coenzyme Q10 (ubiquinone) is an essential component of the electron transport chain, shuttling electrons between Complex I/II and Complex III. It also functions as a powerful antioxidant.
1.1 Mechanism of Action
- Electron carrier: Accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase), transfers to Complex III
- Antioxidant: Reduced form (ubiquinol) scavenges reactive oxygen species, protecting mitochondrial membranes
- Membrane stabilization: Integrates into mitochondrial inner membrane, maintaining structural integrity
- Gene expression: May modulate expression of genes involved in mitochondrial biogenesis
1.2 Ubiquinol vs. Ubiquinone
Two forms are commercially available:
Ubiquinone (oxidized form).
- Standard supplemental form
- Must be reduced to ubiquinol in the body for activity
- Less expensive
- Adequate for most individuals with normal reduction capacity
Ubiquinol (reduced form).
- Active, antioxidant form
- Does not require metabolic conversion
- 2–3\(\\times\) better bioavailability than ubiquinone
- Preferred for patients >40 years, those with impaired mitochondrial function
- More expensive
For ME/CFS patients with suspected mitochondrial impairment, ubiquinol may be preferable despite higher cost.
1.3 Evidence in ME/CFS
- Small studies: Some trials show modest improvement in fatigue and oxidative stress markers
- Mechanistic rationale: Strong theoretical basis given documented mitochondrial dysfunction
- Fibromyalgia evidence: Related condition shows benefit with CoQ10 (300 mg/day ubiquinol)
- Safety profile: Excellent; few side effects even at high doses
- Limitations: No large, well-controlled ME/CFS trials
1.4 Dosing and Bioavailability
Standard Dosing.
- Ubiquinone: 200–400 mg daily in divided doses
- Ubiquinol: 100–300 mg daily (lower dose due to better absorption)
- Timing: Take with fatty meals to enhance absorption (lipophilic compound)
- Duration: Minimum 8–12 weeks to assess benefit; may require 3–6 months
Bioavailability Enhancement.
- Take with fat-containing foods (avocado, nuts, olive oil)
- Soft gel formulations absorb better than powder capsules
- Divide total daily dose (e.g., 200 mg twice daily rather than 400 mg once)
- Consider ubiquinol form if poor response to ubiquinone
1.5 Side Effects
Generally very well-tolerated:
- Mild GI upset (nausea, diarrhea) in <5% of users
- Insomnia if taken late in day (some report increased energy)
- Rare: Rash, dizziness
- Drug interactions: May reduce warfarin effectiveness; monitor INR if anticoagulated
Statins (HMG-CoA reductase inhibitors) deplete CoQ10 by blocking the mevalonate pathway, which is required for both cholesterol and CoQ10 synthesis. This has critical implications for ME/CFS patients:
ME/CFS-specific concern: ME/CFS patients have significantly lower baseline plasma CoQ10 levels than healthy controls, with 44.8% below the lowest control value (Maes et al. 2009). Lower CoQ10 correlates with worse fatigue, autonomic symptoms, and cognitive dysfunction.
Clinical implications:
- Statins may worsen pre-existing CoQ10 deficiency in ME/CFS
- This could exacerbate fatigue, dysautonomia, and cognitive symptoms
- ME/CFS represents a relative contraindication for statin therapy unless CoQ10 is co-supplemented
- If statins are medically necessary (cardiovascular indications), mandatory CoQ10 supplementation (200–400 mg ubiquinol daily) should accompany therapy
- Monitor symptom changes closely when initiating statins in ME/CFS patients
Note on statin pleiotropic effects: Statins possess anti-inflammatory and immunomodulatory properties beyond lipid-lowering (Blum and Shamburek 2005). In autoimmune conditions, these effects can be beneficial (McCarey et al. 2004). However, in ME/CFS, the risk of worsening mitochondrial dysfunction through CoQ10 depletion likely outweighs potential anti-inflammatory benefits, particularly given that alternative anti-inflammatory approaches exist that do not deplete CoQ10.
Energy Profile. Category A (net energy provider). CoQ10 directly supports electron transport at the Complex I/III junction, providing substrate for ATP synthesis rather than consuming it. Supplementation replenishes a cofactor found to be deficient in ME/CFS patients, with deficiency levels correlating with fatigue severity and autonomic symptoms (Maes et al. 2009). One of the safest treatments for energy-depleted patients—it supplies what the system lacks. Ubiquinol form requires no metabolic conversion, making it especially suitable for severe patients with impaired reduction capacity.
2 NADH
Nicotinamide adenine dinucleotide (NADH) is the reduced form of NAD+, a critical coenzyme in cellular energy production.
2.1 Role in Energy Production
- Electron donor: NADH donates electrons to Complex I of electron transport chain
- Glycolysis and TCA cycle: Generated during glucose metabolism and Krebs cycle
- ATP production: Each NADH molecule can generate approximately 2.5 ATP molecules via oxidative phosphorylation
- Lactate metabolism: Required for lactate-to-pyruvate conversion (lactate dehydrogenase reaction)
2.2 Studies in ME/CFS
- Forsyth et al. (1999) (Forsyth et al. 1999): Randomized, double-blind, placebo-controlled crossover trial in 26 ME/CFS patients; 10 mg NADH daily for 4 weeks showed 31% response rate vs. 8% placebo response (statistically significant)
- Santaella et al. (2004) (Santaella, Font, and Disdier 2004): Randomized trial (n=31) comparing NADH to conventional therapy over 24 months; significant improvement in first trimester (p<0.001), but later comparable to active control
- Mixed evidence: Small sample sizes, variable formulations, heterogeneous patient populations; Forsyth study provides strongest evidence but limited replication
- Subset response: May benefit patients with documented NAD+ metabolism abnormalities (per Heng 2025 findings) (Heng et al. 2025)
2.3 Dosing
- Standard dose: 10–20 mg daily on empty stomach (30–60 minutes before breakfast); clinical trial doses were 10 mg (Forsyth et al. 1999) and 20 mg (Castro-Marrero et al. 2021)
- Formulation: Enteric-coated or sublingual to prevent gastric degradation
- Complementary: NAD+ precursors (NR, NMN) serve a different role—see Chapter Supplements and Nutraceuticals, Section D-Ribose Evidence Quality for the two-axis framework
- Duration: Trial for minimum 4–8 weeks
2.4 NADH vs. NAD+ Precursors
NADH and NAD+ precursors serve complementary rather than competing roles: NADH donates electrons directly at Complex I for immediate ATP production, while precursors replenish the broader cellular NAD+ pool for sirtuins, PARP, and metabolic signaling. For the complete two-axis framework and combination rationale, see Chapter Supplements and Nutraceuticals, Section D-Ribose Evidence Quality.
Nicotinamide Riboside (NR).
- Efficiently converts to NAD+ inside cells
- Dose: 300–1000 mg daily
- Better studied than NADH supplementation
- May improve mitochondrial biogenesis
Nicotinamide Mononucleotide (NMN).
- Direct NAD+ precursor
- Dose: 250–500 mg daily
- Emerging evidence for efficacy
- More expensive than NR
For ME/CFS mitochondrial support, the combination of NADH + CoQ10 has the strongest RCT evidence (Castro-Marrero 2021, n=207) (Castro-Marrero et al. 2021), while NR or NMN can be added for NAD+ pool replenishment—a complementary mechanism rather than a replacement.
Energy Profile. Category A (net energy provider). NADH is a direct electron donor to Complex I of the electron transport chain; each molecule can generate approximately 2.5 ATP via oxidative phosphorylation. Minimal processing overhead is required—the molecule enters mitochondrial energy production directly without the enzymatic conversion steps needed by NAD+ precursors. Ideal for energy-depleted patients as a direct substrate rather than a precursor requiring further metabolic steps.
3 D-Ribose
D-ribose is a 5-carbon sugar that serves as the backbone of ATP, ADP, and AMP.
3.1 ATP Synthesis Support
- Rate-limiting substrate: Ribose availability can limit ATP regeneration after depletion
- Purine salvage pathway: Provides ribose-5-phosphate for adenine nucleotide synthesis
- Bypass mechanism: Supplements ribose directly, bypassing pentose phosphate pathway
- Post-ischemic recovery: Accelerates ATP regeneration after energy depletion (established in cardiac ischemia models)
3.2 Evidence in ME/CFS and Fibromyalgia
- Teitelbaum et al. (2006) (Teitelbaum, Johnson, and St Cyr 2006): Open-label pilot study (n=41) in fibromyalgia/ME/CFS patients; 5g D-ribose three times daily showed significant improvement across multiple domains: energy (+45%), sleep (+30%), mental clarity (+30%), pain intensity (-15%), and overall well-being (+30%)
- Mechanism: Post-exertional ATP depletion in ME/CFS may respond to ribose supplementation as ATP backbone precursor; accelerates purine salvage pathway
- Anecdotal support: Widely reported patient benefit; some notice improvement within 1-2 weeks
- Lack of RCTs: No placebo-controlled trials in ME/CFS; open-label design limits certainty despite impressive effect sizes
3.3 Dosing Protocols
- Standard dose: 5 grams (1 scoop) 2–3 times daily
- Total daily dose: 10–15 grams
- Timing: Spread throughout day; some take pre-activity
- Form: Powder dissolved in water or beverages (no capsule form practical due to high dose)
- Loading phase: Some protocols use higher initial doses for 1–2 weeks
- Duration: Effects may appear within 1–2 weeks; trial for 4–6 weeks minimum
3.4 Side Effects
- Hypoglycemia: Ribose can lower blood glucose; problematic for diabetics or those prone to hypoglycemia
- GI symptoms: Diarrhea, nausea if taken on empty stomach
- Lightheadedness: Take with food to minimize
- Caution in diabetes: Monitor blood glucose; may require insulin adjustment
Energy Profile. Category A (net energy provider). D-ribose provides the pentose sugar backbone for ATP regeneration via the purine salvage pathway, bypassing the energy-intensive de novo synthesis route. It converts to the ATP backbone with minimal metabolic processing overhead, making it one of the most direct energy substrates available. Particularly valuable post-exertion when adenine nucleotide pools are depleted and rapid regeneration is needed.
4 L-Carnitine and Acetyl-L-Carnitine
Carnitine is essential for transporting long-chain fatty acids into mitochondria for beta-oxidation.
4.1 Mechanism of Action
L-Carnitine.
- Fatty acid shuttle: Transports long-chain fatty acids across mitochondrial membrane via carnitine palmitoyltransferase (CPT) system
- Energy substrate delivery: Enables fatty acid oxidation for ATP production
- Acetyl-CoA buffering: Helps remove excess acetyl groups during metabolism
Acetyl-L-Carnitine (ALCAR).
- Acetylated form that crosses blood-brain barrier more readily
- Supports neuronal energy metabolism
- May enhance acetylcholine synthesis
- Neuroprotective and cognitive effects
4.2 Evidence in ME/CFS
- Plioplys and Plioplys (1995) (Plioplys and Plioplys 1995): Biomarker study (n=35) demonstrated significantly lower total carnitine, free carnitine, and acylcarnitine levels in CFS patients compared to controls; carnitine levels correlated with functional capacity
- Plioplys and Plioplys (1997) (Plioplys and Plioplys 1997): Treatment study with L-carnitine 3g/day for 8 weeks showed significant improvement in 12 of 18 clinical parameters; provides proof-of-concept for carnitine supplementation
- Vermeulen and Scholte (2004) (Vermeulen and Scholte 2004): Open-label randomized study (n=90, three groups) comparing acetyl-L-carnitine (2g/day), propionyl-L-carnitine (2g/day), and combination over 24 weeks; acetyl-L-carnitine showed 59% improvement in mental fatigue (p=0.015); propionyl-L-carnitine showed 63% improvement in general fatigue (p=0.004); combination therapy showed benefits in both domains
- Malaguarnera et al. (2011) (Malaguarnera et al. 2011): While not ME/CFS-specific, double-blind RCT in hepatic encephalopathy demonstrated acetyl-L-carnitine’s efficacy for reducing fatigue and improving cognitive function; supports mechanism of action
- Mechanisms: Addresses documented carnitine deficiency (Plioplys and Plioplys 1995), improves fatty acid oxidation, supports mitochondrial function
- Subset specificity: May particularly help patients with acylcarnitine abnormalities on metabolomic testing; carnitine levels could serve as treatment-response biomarker
4.3 Dosing
L-Carnitine.
- Dose: 1000–3000 mg daily in divided doses
- Form: L-carnitine tartrate or L-carnitine fumarate (avoid D-carnitine)
- Timing: Between meals for optimal absorption
Acetyl-L-Carnitine.
- Dose: 2000 mg daily in divided doses (based on Vermeulen 2004 study showing efficacy at 2g/day for mental fatigue) (Vermeulen and Scholte 2004)
- Cognitive focus: Preferred for brain fog and cognitive symptoms; 59% improvement rate in mental fatigue domain
- Timing: Morning and early afternoon (may cause alertness)
Propionyl-L-Carnitine.
- Dose: 2000 mg daily in divided doses (based on Vermeulen 2004 study showing efficacy for general fatigue) (Vermeulen and Scholte 2004)
- Physical fatigue focus: Preferred for general fatigue and physical exhaustion; 63% improvement rate
- Less commonly available: May require compounding pharmacy or specialty suppliers
Combination. Some patients use both forms: L-carnitine for peripheral energy metabolism + ALCAR for cognitive support.
4.4 Side Effects
- Body odor: “Fishy” smell in some individuals (genetic variation in FMO3 enzyme)
- GI upset: Nausea, diarrhea at high doses
- Insomnia: If taken late in day
- TMAO concerns: Gut bacteria convert carnitine to TMAO (trimethylamine N-oxide), linked to cardiovascular risk in some studies; clinical significance in ME/CFS unclear
Energy Profile. Category A (net energy provider). Carnitine enables fatty acid oxidation, the body’s most energy-dense metabolic pathway (yielding substantially more ATP per carbon than glucose). ALCAR additionally crosses the blood-brain barrier to support neuronal energy metabolism. Minimal processing overhead relative to the substantial energy yield from improved fatty acid transport into mitochondria. Particularly relevant where documented carnitine deficiency limits beta-oxidation capacity.
5 Alpha-Lipoic Acid
Alpha-lipoic acid (ALA) is a mitochondrial cofactor and powerful antioxidant.
5.1 Mechanism of Action
- Cofactor for pyruvate dehydrogenase: Essential for converting pyruvate to acetyl-CoA (entry into TCA cycle)
- Cofactor for alpha-ketoglutarate dehydrogenase: Critical TCA cycle enzyme
- Antioxidant: Scavenges multiple reactive oxygen species; regenerates other antioxidants (vitamins C, E, glutathione)
- Metal chelation: Binds toxic metals, potentially protective
- Blood-brain barrier penetration: Can protect neural mitochondria
5.2 Evidence
- Diabetic neuropathy: Well-established benefit in diabetic peripheral neuropathy (600–1800 mg/day)
- ME/CFS rationale: Theoretical benefit given mitochondrial dysfunction and oxidative stress
- Limited ME/CFS trials: No large controlled studies specific to ME/CFS
- Small fiber neuropathy: May help subset with documented SFN (common in ME/CFS)
5.3 Dosing
- Standard dose: 300–600 mg daily in divided doses
- High-dose protocol: Up to 1200–1800 mg/day used in diabetic neuropathy studies
- R-lipoic acid vs. racemic: R-form is the naturally occurring, bioactive enantiomer; may be more effective
- Timing: Take on empty stomach 30–60 minutes before meals for optimal absorption
- Duration: Minimum 8–12 weeks; neurological benefits may require months
5.4 Side Effects
- Hypoglycemia: Can lower blood glucose; caution in diabetics
- Nausea: Particularly at higher doses
- Skin rash: Rare
- Biotin depletion: High-dose ALA may compete with biotin; consider biotin supplementation (5–10 mg/day) with long-term high-dose ALA
Energy Profile. Category A–B (provider to neutral). ALA serves as an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase—rate-limiting TCA cycle enzymes that cannot function without it. Net energy effect is positive: ALA enables energy production rather than consuming it. It additionally regenerates antioxidants (vitamins C, E, glutathione), reducing the metabolic cost of chronic oxidative stress. Safe for energy-depleted patients.
6 Combination Mitochondrial Support Protocols
Many ME/CFS specialists recommend combining multiple mitochondrial supplements:
6.1 Basic Mitochondrial Stack
- CoQ10 (ubiquinol) 200–300 mg daily
- B-complex vitamins (B1, B2, B3, B5 for TCA cycle cofactors)
- Magnesium 400–600 mg daily (ATP-Mg complex, hundreds of enzymatic reactions)
- Vitamin D 2000–5000 IU daily (mitochondrial gene expression)
6.2 Enhanced Protocol
Add to basic stack:
- D-ribose 10–15 g daily (ATP regeneration)
- L-carnitine 1500–3000 mg daily (fatty acid transport)
- Alpha-lipoic acid 600–1200 mg daily (antioxidant, cofactor)
- NAD+ precursor (NR 300–1000 mg or NMN 250–500 mg)
6.3 Implementation Strategy
Severe ME/CFS patients should begin with the most minimal subset (CoQ10 alone or CoQ10 + magnesium) and introduce one supplement at a time with 2–4 week intervals, given documented hypersensitivity to new compounds. Patients on diabetes medication should note the ALA hypoglycaemia risk (see above) before including it in any stack.
- Start with basic stack for 4–6 weeks
- Add one additional supplement at a time, spaced 2–4 weeks apart
- Monitor response to each addition with symptom diary
- Discontinue supplements showing no benefit after 8–12 weeks
- Adjust doses based on tolerance and response
7 Limitations and Realistic Expectations
- Modest benefits: Mitochondrial supplements typically provide 10–30% improvement, not remission
- Subset specificity: May help those with documented mitochondrial dysfunction more than others
- Cost burden: Comprehensive protocols cost $100–300/month
- Evidence gaps: Most lack large, high-quality RCTs in ME/CFS
- Supportive, not curative: Address downstream consequences, not root cause
- Best as foundation: Work optimally when combined with pacing, autonomic support, sleep optimization
Mitochondrial support represents a rational therapeutic approach given documented energy metabolism abnormalities, though individual responses vary widely.
8 Coenzyme Q10 (CoQ10)
Statins (HMG-CoA reductase inhibitors) deplete CoQ10 by blocking the mevalonate pathway, which is required for both cholesterol and CoQ10 synthesis. This has critical implications for ME/CFS patients:
ME/CFS-specific concern: ME/CFS patients have significantly lower baseline plasma CoQ10 levels than healthy controls, with 44.8% below the lowest control value (Maes et al. 2009). Lower CoQ10 correlates with worse fatigue, autonomic symptoms, and cognitive dysfunction.
Clinical implications:
- Statins may worsen pre-existing CoQ10 deficiency in ME/CFS
- This could exacerbate fatigue, dysautonomia, and cognitive symptoms
- ME/CFS represents a relative contraindication for statin therapy unless CoQ10 is co-supplemented
- If statins are medically necessary (cardiovascular indications), mandatory CoQ10 supplementation (200–400 mg ubiquinol daily) should accompany therapy
- Monitor symptom changes closely when initiating statins in ME/CFS patients
Note on statin pleiotropic effects: Statins possess anti-inflammatory and immunomodulatory properties beyond lipid-lowering (Blum and Shamburek 2005). In autoimmune conditions, these effects can be beneficial (McCarey et al. 2004). However, in ME/CFS, the risk of worsening mitochondrial dysfunction through CoQ10 depletion likely outweighs potential anti-inflammatory benefits, particularly given that alternative anti-inflammatory approaches exist that do not deplete CoQ10.
8.1 Mechanism of Action
8.2 Ubiquinol vs. Ubiquinone
8.3 Evidence in ME/CFS
8.4 Dosing and Bioavailability
8.5 Side Effects
9 NADH
9.1 Role in Energy Production
9.2 Studies in ME/CFS
9.3 Dosing
9.4 NADH vs. NAD+ Precursors
10 D-Ribose
10.1 ATP Synthesis Support
10.2 Evidence in ME/CFS and Fibromyalgia
10.3 Dosing Protocols
10.4 Side Effects
11 L-Carnitine and Acetyl-L-Carnitine
11.1 Mechanism of Action
11.2 Evidence in ME/CFS
11.3 Dosing
11.4 Side Effects
12 Alpha-Lipoic Acid
12.1 Mechanism of Action
12.2 Evidence
12.3 Dosing
12.4 Side Effects
13 Combination Mitochondrial Support Protocols
13.1 Basic Mitochondrial Stack
13.2 Enhanced Protocol
13.3 Implementation Strategy
14 Limitations and Realistic Expectations
Statins (HMG-CoA reductase inhibitors) deplete CoQ10 by blocking the mevalonate pathway, which is required for both cholesterol and CoQ10 synthesis. This has critical implications for ME/CFS patients:
ME/CFS-specific concern: ME/CFS patients have significantly lower baseline plasma CoQ10 levels than healthy controls, with 44.8% below the lowest control value (Maes et al. 2009). Lower CoQ10 correlates with worse fatigue, autonomic symptoms, and cognitive dysfunction.
Clinical implications:
- Statins may worsen pre-existing CoQ10 deficiency in ME/CFS
- This could exacerbate fatigue, dysautonomia, and cognitive symptoms
- ME/CFS represents a relative contraindication for statin therapy unless CoQ10 is co-supplemented
- If statins are medically necessary (cardiovascular indications), mandatory CoQ10 supplementation (200–400 mg ubiquinol daily) should accompany therapy
- Monitor symptom changes closely when initiating statins in ME/CFS patients
Note on statin pleiotropic effects: Statins possess anti-inflammatory and immunomodulatory properties beyond lipid-lowering (Blum and Shamburek 2005). In autoimmune conditions, these effects can be beneficial (McCarey et al. 2004). However, in ME/CFS, the risk of worsening mitochondrial dysfunction through CoQ10 depletion likely outweighs potential anti-inflammatory benefits, particularly given that alternative anti-inflammatory approaches exist that do not deplete CoQ10.